- Home
- RPD vs SPRY Comparison
RPD vs SPRY Comparison
Compare RPD & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | SPRY |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.5M | 788.5M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPD | SPRY |
|---|---|---|
| Price | $7.03 | $8.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | $15.05 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $685,083,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $0.54 | $81.64 |
| P/E Ratio | $362.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.97 | $6.66 |
| 52 Week High | $25.85 | $18.63 |
Technical Indicators
Market Signals| Indicator | RPD | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 56.13 |
| Support Level | $5.97 | $7.82 |
| Resistance Level | $19.70 | $8.61 |
| Average True Range (ATR) | 0.47 | 0.55 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 68.81 | 67.46 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.